What are the Historical Developments and Current Growth Metrics of the Liposomal Drug Delivery Devices Market?
The liposomal drug delivery devices market has seen considerable growth due to a variety of factors.
• In the past few years, the market for liposomal drug delivery devices has seen notable expansion. The market is projected to swell from $4.89 billion in 2024 to $5.38 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.2%.
Factors contributing to growth in the historical period include the progress made in drug delivery techniques, biomedical research, clinical confirmations, therapeutic applications, and improvements in biocompatibility.
What Will Be The Liposomal Drug Delivery Devices Market Size In The Future?
The liposomal drug delivery devices market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of liposomal drug delivery devices is predicted to expand significantly in the upcoming years. With a Compound Annual Growth Rate (CAGR) of 12.4%, it is forecasted to reach a worth of $8.61 billion by 2029. Factors contributing to this projected growth in the forecast period encompass the advancement of targeted therapies, clinical confirmations and examinations, focus on individualized medicine, the evolution of combination treatments, and alterations in the regulatory environment. Prominent trends anticipated during the forecast period involve the use of biocompatible liposomal materials, delivery system innovations, applications in the field of oncology, combination treatments, and the creation of tailored liposome formulations.
What Are The Essential Drivers Behind The Growth Of The Liposomal Drug Delivery Devices Market?
The global increase in cancer cases is expected to fuel the expansion of the liposomal drug delivery devices market in the projected period. These delivery systems are utilized for specific cancer treatments in radiation, chemotherapy, and surgical resection. For example, data from the UK-based Macmillan Cancer Support revealed in June 2022 that the number of individuals living with cancer hit 3 million in 2022, with expectations of nearly 3.5 million by 2025 and 4 million by 2030 in the UK. As such, the escalating rate of cancer cases worldwide is expected to stimulate demand for the liposomal drug delivery devices market in the upcoming years.
What are the Market Segments in the Liposomal Drug Delivery Devices Market?
The liposomal drug delivery devices market covered in this report is segmented –
1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types
2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy
3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users
Subsegments:
1) By Liposomal Doxorubicin: Conventional Liposomal Doxorubicin, PEGylated Liposomal Doxorubicin
2) By Liposomal Paclitaxel: Conventional Liposomal Paclitaxel, PEGylated Liposomal Paclitaxel
3) By Liposomal Amphotericin B: Conventional Liposomal Amphotericin B, PEGylated Liposomal Amphotericin B
4) By Other Types: Liposomal Irinotecan, Liposomal Vincristine, Liposomal Cytarabine
Pre-Book The Liposomal Drug Delivery Devices Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Liposomal Drug Delivery Devices Market?
Numerous leading corporations are adopting various strategic measures such as creating new products, predicted to be a significant trend in the liposomal drug delivery devices market. Different firms are uniting to formulate liposomal drug delivery systems as a means to broaden their range of products and extend their global operations. To illustrate, in May 2024, Insmed, Inc., a biotechnology company from the US, released data from the ARISE study of ARIKAYCE (amikacin liposome inhalation suspension). The results showed that patients treated with ARIKAYCE outperformed those in the comparator group (a macrolide-based multi-drug regimen) as judged by the QOL-B tool, with 43.8% of patients witnessing an improvement in their QOL-B respiratory score.
Who Are the Key Players in the Liposomal Drug Delivery Devices Market?
Major companies operating in the liposomal drug delivery devices market include:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Novartis AG
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• CSPC Pharmaceutical Group Limited
• Ipsen SA
• Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd.
• Nanomerics Ltd.
• Luye Pharma Group Ltd.
• Leadiant Biosciences Inc.
• Pacira Biosciences Inc.
• Nippon Kayaku Co. Ltd.
• Celsion Corporation
• Acrotech Biopharma Inc.
• Aphios Pharma LLC
• CytImmune Sciences Inc.
• NanoSphere Health Sciences Inc.
• Cel-Sci Corporation
• Lipoid GmbH
• Liposome Company Inc.
• Liposome Research Days Corporation
• Taiwan Liposome Company
• T&T Scientific Corporation
What are the Regional Insights into the Liposomal Drug Delivery Devices Market?
North America was the largest region in the liposomal drug delivery devices market in 2024. Asia-Pacific was the second-largest region in the global liposomal drug delivery devices market share. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
